Suppr超能文献

建议将氯硝西泮与普拉克索用于治疗不宁腿综合征患者的等效剂量。

Proposed dose equivalence between clonazepam and pramipexole in patients with restless legs syndrome.

机构信息

Department of Neuropsychiatry, Kagawa University School of Medicine, 1750-1 Ikenobe, Miki, Kida, Kagawa 761-0793, Japan.

出版信息

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):522-6. doi: 10.1016/j.pnpbp.2010.02.011. Epub 2010 Feb 13.

Abstract

BACKGROUND

Dopamine agonists are accepted as the first-line medications for restless legs syndrome (RLS). In some Asian countries, clonazepam is one of the prevalent medications for RLS because of its effect on sleep disturbances. To date, there have not been any studies that examined equivalent doses of pramipexole and clonazepam. To evaluate equivalent doses of pramipexole and clonazepam in RLS, we investigated the efficacy and tolerability after conversion from clonazepam to pramipexole, and examined dose equivalence between the two prescriptions.

METHODS

In a prospective, open-label, multicenter study, 26 RLS patients treated with clonazepam (mean age: 69.2+/-11.0years old) were enrolled and then rapidly switched to pramipexole using a conversion calculation of 4:1 for daily doses. Then the daily dose of pramipexole was up titrated or tapered by 0.125mg/day at each subsequent examination. RLS symptoms and daytime somnolence were evaluated using the International RLS Study Group rating scale (IRLS), Clinical Global Impressions - Severity of illness (CGI-S) and the Epworth Sleepiness Scale (ESS), respectively.

RESULTS

Conversion from clonazepam to pramipexole resulted in significant reductions of IRLS (16.3+/-8.7 to 9.1+/-6.3) and ESS (6.5+/-4.2 to 4.4+/-3.2). CGI scores demonstrated improvement after conversion. In 4 patients (15%), adverse events such as somnolence, sensation of oppression in the lower limbs, diarrhea, or nausea were present. Correlation analysis demonstrated a significant relationship between these daily doses. Spearman's correlation coefficient was 0.662. Our study, however, has some limitations since it is an open-label trial and includes only 26 patients. Further studies using a double-blind design or a crossover design are recommended.

CONCLUSIONS

Statistical analysis demonstrated a 4:1 conversion for clonazepam to pramipexole. When switchover from clonazepam to pramipexole is done, this conversion ratio may be helpful to determine the initial dose of pramipexole for treating RLS.

摘要

背景

多巴胺激动剂被认为是治疗不安腿综合征(RLS)的一线药物。在一些亚洲国家,由于氯硝西泮对睡眠障碍有影响,它是治疗 RLS 的常用药物之一。迄今为止,还没有任何研究检查过普拉克索和氯硝西泮的等效剂量。为了评估普拉克索和氯硝西泮在 RLS 中的等效剂量,我们研究了从氯硝西泮转换为普拉克索后的疗效和耐受性,并检查了两种处方之间的剂量等效性。

方法

在一项前瞻性、开放标签、多中心研究中,纳入了 26 名接受氯硝西泮治疗的 RLS 患者(平均年龄:69.2+/-11.0 岁),然后根据每日剂量以 4:1 的转换计算快速转换为普拉克索。然后,在每次后续检查时,以 0.125mg/天的速度逐渐增加或减少普拉克索的日剂量。使用国际 RLS 研究组评分量表(IRLS)、临床总体印象-严重程度(CGI-S)和 Epworth 嗜睡量表(ESS)分别评估 RLS 症状和白天嗜睡。

结果

从氯硝西泮转换为普拉克索后,IRLS(16.3+/-8.7 至 9.1+/-6.3)和 ESS(6.5+/-4.2 至 4.4+/-3.2)显著降低。转换后 CGI 评分显示改善。在 4 名患者(15%)中,出现了不良反应,如嗜睡、下肢压迫感、腹泻或恶心。相关性分析表明这些日剂量之间存在显著关系。Spearman 相关系数为 0.662。然而,由于本研究是一项开放标签试验,且仅包括 26 名患者,因此存在一些局限性。建议使用双盲设计或交叉设计进行进一步研究。

结论

统计分析表明,氯硝西泮转换为普拉克索的比例为 4:1。当从氯硝西泮转换为普拉克索时,这个转换比例可能有助于确定治疗 RLS 的普拉克索初始剂量。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验